I don’t see this very often, but it looks like there’s a little battle brewing between Ian Cooper and Rob Fannon … or probably more precisely, between Stansberry & Associates and Angel Publishing. I don’t know if this has anything to do with it, but the two seem linked in several “sincerest form of flattery” […]

I haven’t written much about Rob Fannon and his Phase 1 Investor newsletter lately — this is the high end newsletter published by the folks at Stansberry and Associates, it’ll run you about $4,500 a year, and it’s largely focused on biotech companies. So is their advice worth more than the advice from less expensive […]

This one comes in from Rob Fannon’s Medical Investor, another publication of Stansberry and Associates — we’ve seen a few of his teasers before, with actually some quite good results on their ideas for “SNiP Investments” and a few others. This time, as with so many Stansberry ads, there’s again an invented term to juice […]